Stock ASRT ASSERTIO HOLDINGS
Add to a list
Suspension of trading

Assertio Holdings Share Price

Stocks

ASRT

US04546C3043

Pharmaceuticals

Delayed
Nasdaq
01:30:00 16/06/2026 am IST 		5-day change 1st Jan Change
23.50 USD +0.09% Intraday chart for Assertio Holdings -.--% +159.10%
17/06 Assertio Holdings Completes Merger With Zydus Lifesciences MT
17/06 Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026 CI

Valuation: Assertio Holdings

Market Cap 15Cr 13Cr 12Cr 11Cr 21Cr 1.45TCr 21Cr 143.8Cr 56Cr 729.91Cr 57Cr 56Cr 2.41TCr P/E 2027 *
-
P/E 2028 * -
Enterprise Value 13Cr 11Cr 10Cr 9.44Cr 18Cr 1.23TCr 18Cr 121.88Cr 48Cr 618.63Cr 48Cr 47Cr 2.05TCr EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
99.05%
Yield 2027 *
-
Yield 2028 * -
* Estimated data More valuation ratios

Chart: Assertio Holdings

Dynamic Chart

Latest news : Assertio Holdings

17/06 Assertio Holdings Completes Merger With Zydus Lifesciences MT
17/06 Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026 CI
16/06 Assertio Holdings, Inc.(NasdaqCM:ASRT) dropped from S&P TMI Index CI
16/06 Assertio Holdings, Inc.(NasdaqGM:ASRT) dropped from NASDAQ Composite Index CI
16/06 Zydus Worldwide DMCC completed the acquisition of Assertio Holdings, Inc.. CI
13/05 Garda Therapeutics, Inc. cancelled the acquisition of Assertio Holdings, Inc.. CI
13/05 Zydus Worldwide DMCC entered into definitive agreement to acquire Assertio Holdings, Inc. for approximately $160 million. CI
13/05 Assertio to be acquired by Zydus Worldwide DMCC for $23.50 per share in cash RE
13/05 Assertio Board Approves $23.50-Per-Share Sale to Zydus Worldwide DMCC MT
13/05 Zydus to Acquire Assertio for $166.4 Million DJ
09/05 Assertio Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
08/05 Assertio and Garda mutually agree to delay launch of tender offer RE
05/05 Assertio and Garda mutually agree to postpone commencement of tender offer RE
More news

Last Transcript: Assertio Holdings

Logo Assertio Holdings
Assertio Holdings, Inc., Q4 2025 Earnings Call, Mar 16, 2026
17/03
More transcripts

Analysts' recommendations: Assertio Holdings

09/04 HC Wainwright Downgrades Assertio Holdings to Neutral From Buy, Adjusts Price Target to $18 From $35 MT
03/24/03 HC Wainwright Initiates Assertio Holdings at Buy With $4 Price Target MT
12/24/12 Lake Street Adjusts Assertio Therapeutics' Price Target to $3 From $4, Maintains Buy Rating MT
10/23/10 BWS Financial Adjusts Assertio Therapeutics' Price Target to $10 From $8, Keeps Buy Rating MT
10/23/10 Lake Street Adjusts Assertio Therapeutics' Price Target to $9 From $8, Keeps Buy Rating MT
More recommendations

Press Releases: Assertio Holdings

17/06 Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027 BU
19/05 Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT BU
13/05 Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash BU
08/05 Assertio and Garda Mutually Agree to Delay Launch of Tender Offer BU
05/05 Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer BU
More press releases

Quotes and Performance

1 day+0.09%
3 months+0.26%
6 months+98.48%
Current year+159.10%
More quotes

Course Extremes

Current year 9.11
Extreme 9.11
 23.5
1 year 8.61
Extreme 8.61
 23.5
3 years 7.71
Extreme 7.705496
 52.05
5 years 7.71
Extreme 7.705496
 120.15
10 years 7.71
Extreme 7.705496
 1,621.19
More quotes

Managers and Directors: Assertio Holdings

Director TitleAgeSince
Ravi Yadavar BRD
 Director/Board Member 26 16/06/2026
Punit Patel BRD
 Director/Board Member - 16/06/2026
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
05/05/26
David Stark
Free

Director

4,851 0.0753%
02/03/26
Ajay Patel
Free

Chief Financial Officer

39,932 0.6223%
21/02/26
Paul Schwichtenberg
Fiscal year

Chairperson

2,852 0.0444%
Transaction History

Other Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
ASSERTIO HOLDINGS Stock Assertio Holdings
+0.09%-.--%+101.50%-52.38% 15Cr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+0.85%+6.40%+76.89%+128.28% 1,10900Cr
JOHNSON & JOHNSON Stock Johnson & Johnson
+1.37%+4.25%+51.69%+62.19% 64TCr
ABBVIE INC. Stock AbbVie Inc.
+1.15%+6.61%+26.94%+77.10% 46TCr
ROCHE HOLDING AG Stock Roche Holding AG
+1.02%+5.77%+43.09%+47.70% 37TCr
NOVARTIS AG Stock Novartis AG
+0.85%+4.07%+23.88%+41.58% 30TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+1.26%+6.81%+1.59%+14.67% 26TCr
AMGEN INC. Stock Amgen Inc.
+1.89%+5.64%+48.30%+68.25% 23TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+1.59%+2.09%-15.52%-52.29% 20TCr
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
+1.83%+5.95%+26.22%+93.04% 18TCr
Average +1.22%+2.73%+38.46%+42.81% 37.61TCr
Weighted average by Cap. +1.21%+3.26%+44.53%+72.80%
See all sector performances

Financials

2027 *2028 *
Net sales - -
Net income 4L 3L 3L 3L 6L 3.83Cr 6L 37.88L 14.77L 1.92Cr 15.02L 14.69L 6.36Cr -
Net Debt - -
* Estimated data More financial data

Company Profile

Logo Assertio Holdings
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Employees
53
Sector
Pharmaceuticals
More about the company
  1. Stock Market
  2. Stocks
  3. ASRT Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong